Skip to main content
Midas Edge

FENNEC PHARMACEUTICALS INC.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

FENC$10.58-2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

1.Financial Statements – See Index to Financial Statements on page F-1.
2.All schedules are omitted as the information required is inapplicable or the information is presented in the financial statements.
3.Exhibits:
​​
ExhibitNo.​ ​ ​Description​ ​ ​Location
3.1Notice of Articles dated August 25, 2011Exhibit 3.2I to the Form 8-K of the Company filed August 26, 2011
3.2Articles dated August 25, 2011Exhibit 3.2II to the Form 8-K of the Company filed August 26, 2011
3.3Notice of Alteration Dated September 3, 2014Exhibit 3.1 to the Form 8-K of the Company filed September 9, 2014
4.1​Fennec Pharmaceuticals, Inc. Description of the Registrant’s Securities​Exhibit 4.1 to the Form 10-K of the Company filed March 29, 2024
​​​​​
10.1Fennec Pharmaceuticals, Inc. 2020 Equity Incentive Plan*Schedule B to the Management Proxy Circular of the Company filed April 25, 2025
10.2Executive Employment Agreement dated May 3, 2010 by and between Fennec Pharmaceuticals Inc. and Rostislav Raykov*Exhibit 10.28 to the Form 10-Q of the Company filed May 14, 2010
10.3Form of Independent Director Agreement, dated May 3, 2010Exhibit 10.31 to the Form 10-Q of the Company filed May 14, 2010
10.4Executive Employment Agreement dated November 12, 2015 by and between Fennec Pharmaceuticals Inc. and Robert Andrade*Exhibit 10.40 to the Form 10-Q of the Company filed November 12, 2015
10.5Form of Stock Option Award Agreement under 2020 Equity Incentive Plan*Exhibit 10.5 to the Form 10-K of the Company filed March 26, 2025
10.6Form of Restricted Stock Award Agreement under 2020 Equity Incentive Plan*Exhibit 10.6 to the Form 10-K of the Company filed March 26, 2025
​​​​​
10.7​Confidential Separation Agreement between Fennec Pharmaceuticals (EU) Limited, Fennec Pharmaceuticals Inc., and Adrian Haigh, dated June 30, 2024*​Exhibit 10.1 to the Form 8-K of the Company filed July 2, 2024
​​​​​
10.8​Confidential Separation Agreement between Fennec Pharmaceuticals, Inc. and Rostislav Raykov, dated August 5, 2024*​Exhibit 10.1 to the Form 8-K of the Company filed August 7, 2024
​​​​​
10.9Executive Employment Agreement between Fennec Pharmaceuticals, Inc. and Jeffrey S. Hackman, dated August 5, 2024*Exhibit 10.2 to the Form 8-K of the Company filed August 7, 2024
​​​​​
​​
ExhibitNo.​ ​ ​Description​ ​ ​Location
10.10​At The Market Offering Agreement, dated October 30, 2020, between Fennec Pharmaceuticals Inc. and H.C. Wainwright & Co., LLC​Exhibit 1.1 to the Form 8-K of the Company filed October 30, 2020
10.11​Securities Purchase Agreement, dated as of August 1, 2022, by and between Fennec Pharmaceuticals Inc. and Petrichor Opportunities Fund I LP​Exhibit 10.1 to the form 8-K of the Company filed August 1, 2022
​​​​​
10.12​First Closing Senior Secured Convertible Note, dated August 19, 2022, by and between Fennec Pharmaceuticals Inc. and Petrichor Opportunities Fund I LP​Exhibit 4.1 to the form 8-K of the Company filed August 22, 2022
​​​​​
10.13​Second Closing Senior Secured Convertible Note, dated September 23, 2022, by and between Fennec Pharmaceuticals Inc. and Petrichor Opportunities Fund I LP​Exhibit 4.1 to the form 8-K of the Company filed September 26, 2022
​​​​​
10.14​First Amendment to Securities Purchase Agreement, dated as of December 4, 2023, between Fennec Pharmaceuticals Inc. and Petrichor Opportunities Fund I LP​Exhibit 10.1 to the Form 8-K of the Company filed December 6, 2023
​​​​​
10.15​Third Closing Senior Secured Convertible Note, dated as of December 4, 2023, between Fennec Pharmaceuticals Inc. and Petrichor Opportunities Fund I LP​Exhibit 4.1 to the Form 8-K of the Company filed December 6, 2023
​​​​​
10.16​License and Supply Agreement, dated March 15, 2024, between Fennec Pharmaceuticals, Inc. and Norgine Pharma UK Limited​Exhibit 10.1 to the Form 8-K of the Company filed March 21, 2024
​​​​​
10.17​Waiver and Redemption Agreement, dated December 18, 2024, between Fennec Pharmaceuticals Inc. and Petrichor Opportunities Fund I LP​Exhibit 10.1 to the Form 8-K of the Company filed December 20, 2024
​​​​​
19Fennec Pharmaceuticals, Inc. Insider Trading Policy, dated July 11, 2009.Exhibit 10.16 to the Form 10-K of the Company filed March 29, 2024
21SubsidiariesExhibit 21 to the 10-K of the Company filed February 14, 2020
23.1Consent of Haskell & White LLP, Independent Registered Public Accounting FirmFiled herewith
​​​​​
31.1​Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002​Filed herewith
​​
31.2​Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002​Filed herewith
​​
32.1​Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002​Filed herewith
​​
97​Fennec Pharmaceuticals, Inc. Incentive Compensation Recovery Policy​Exhibit 97 to the Form 10-K of the Company filed March 29, 2024
​​​​​
99.1​Press Release for Fiscal Year Ended December 31, 2025​Filed herewith
​​
ExhibitNo.​ ​ ​Description​ ​ ​Location
​​
101.1​Interactive Data File​Filed herewith
​​​​​
104​Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document​Filed herewith
*Indicates a management contract or compensatory plan.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.